(Q44416908)

2 December 2017

title

Benchmarking safety pharmacology regulatory packages and best practice (English)

1 reference

2 December 2017

1 reference

1 reference

Silvana Lindgren

1

1 reference

2 December 2017

Alan S Bass

2

1 reference

2 December 2017

Richard Briscoe

3

1 reference

2 December 2017

Kristy Bruse

4

1 reference

2 December 2017

Gregory S Friedrichs

5

1 reference

2 December 2017

Mary Jeanne Kallman

6

1 reference

2 December 2017

Carrie Markgraf

7

1 reference

2 December 2017

Leslie Patmore

8

1 reference

2 December 2017

Michael K Pugsley

9

1 reference

2 December 2017

publication date

19 July 2008

1 reference

Journal of Pharmacological and Toxicological Methods

2 December 2017

published in

1 reference

2 December 2017

volume

58

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

99-109

1 reference

Moving towards better predictors of drug-induced torsades de pointes

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Origins, practices and future of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

A novel method for chronic measurement of respiratory function in the conscious monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

A novel method for chronic measurement of pleural pressure in conscious rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Drug-induced prolongation of the QT interval: why the regulatory concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2008.07.001

10.1016/J.VASCN.2008.07.001

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference